Skip to main content

Table 4 Regression models predicting the use of tocilizumab, either combination or monotherapy, using baseline only or baseline and follow-up variables, odds ratios (95% confidence intervals)

From: The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy

 

Baseline only

Baseline and follow-up

Age, per year

0.99 (0.98, 0.99)

1.05 (1.02, 1.08)

Male vs. female

0.91 (0.75, 1.11)

1.03 (0.48, 2.20)

Disease duration, years

0.99 (0.99, 1.01)

1.06 (1.03, 1.08)

Serologic status*

 Negative

Reference

Reference

 Positive

0.66 (0.56–0.78

0.11 (0.04, 0.29)

 Missing

0.42 (0.29–0.60)

0.88 (0.38, 2.06)

DMARD use**

 csDMARD, baseline

0.71 (0.59–0.86)

0.18 (0.12, 0.27)

 TNFi

–

0.48 (0.26, 0.90)

 nonTNFi nonTCZ bDMARD

–

4.59 (2.91, 7.25)

 Only csDMARD

–

5.83 (3.73, 9.13)

 No DMARDs

–

0.40 (0.18, 0.88)

Glucocorticoid use

–

0.87 (0.61, 1.23)

CDAI, Severe

–

Reference

 Moderate

–

0.65 (0.46, 0.91)

 Low

–

0.48 (0.33, 0.70)

 Remission

–

0.20 (0.11, 0.37)

Comorbidities, count#

–

1.16 (1.11, 1.22)

  1. Notes: Odds ratios (95% confidence intervals). Baseline models used logistic regression. Models with follow-up data used mixed generalized linear regression
  2. TCZ tocilizumab; DMARD disease-modifying anti-rheumatic drug; csDMARDs conventional synthetic DMARDs; nonTNFi nonTCZ bDMARD includes all JAK inhibitors, abatacept, and rituximab
  3. ---Not considered at baseline or not significant in univariable screen so not considered in multivariable model or withheld from the model because of problems with convergence
  4. *Serologic status defined as a positive if either rheumatoid factor or anti-CCP antibody were ever positive up to the relevant reference point
  5. **Reference category for DMARD use is the non-use of a give DMARD
  6. #Comorbidities are noted in Table 1. Clinical disease activity index (CDAI) categories defined as remission (CDAI < 2.8), low (CDAI 2.9–10.0), moderate (CDAI 10.1–22.0), and high (CDAI > 22.1)
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us